Signet Therapeutics today announced,SIGNET's SIGX1094, the world’s first targeted drug for diffuse gastric cancer, will present its latest preclinical research data at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The core differentiation mechanism underlying the drug’s superior preclinical efficacy will be disclosed for the first time — dual inhibition of FAK and its key binding factor SRC. This makes SIGX1094 the world’s first FAK/SRC dual-target inhibitor to enter clinical trials.As the most influential academic conference in the field of global cancer research, the 2025 AACR Annual Meeting will be held in Chicago, USA, from April 25 to 30.
FAK and its key binding factor SRC form a complex to activate downstream pathways. Therefore, in the drug development process, single inhibition of FAK or SRC will be compensatorily offset by the other, significantly reducing the drug's anti-tumor effect. SIGNET utilized phenotypic screening of organoid disease models and integrated AI-based drug design to develop the first FAK/SRC dual-target inhibitor, greatly enhancing the drug's anti-tumor efficacy.
SIGNET will present the following report at the upcoming AACR conference, and the company's co-founder, Dr. Adam Bass, will attend and deliver the presentation on this cutting-edge result.
The AACR Annual Meeting, organized by the American Association for Cancer Research, is an authoritative academic platform in the field of oncology. It brings together scientists, clinical experts, healthcare practitioners, and patient representatives from around the world each year to discuss innovative advancements spanning cancer prevention, basic research, translational medicine, clinical treatment, and patient care. The release of the SIGX1094 study data at this conference will highlight SIGNET's breakthrough progress in targeted therapies for diffuse gastric cancer.
About SIGNET
SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and certified as a National High-tech Enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since secured nearly 220 million yuan in financing and project funding. Currently, the company has four drug pipelines, with the first pipeline developing SIGX1094, the world’s first targeted drug for diffuse gastric cancer. It has obtained IND approval from both the U.S. FDA and China's NMPA, and received Orphan Drug Designation and Fast Track Designation from the U.S. FDA, advancing into Phase I clinical trials.
Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "Full of Hope, Investigating Things to Gain Knowledge." The company leverages patient-derived organoid disease models that closely resemble genomic characteristics for critical applications in drug efficacy evaluation and novel target discovery. By integrating AI-powered screening, synthesis, and optimization of small-molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has a 1200㎡ R&D facility and a 500㎡ experimental animal housing area. SIGNET’s organoid platform not only serves its own drug pipeline but also actively empowers large pharmaceutical enterprises in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the creation of more innovative drugs.
1
END
1
